https://prabadinews.com/

Email

weborders@prabadincorp.com

Call us

+1 (786)-332-3938
january-–-march-2025-|-potential-signals-of-serious-risks/new-safety-information-identified-by-the-fda-adverse-event-reporting-system-(faers) Drug Test
  • June 30, 2025

January – March 2025 | Potential Signals of Serious Risks/New Safety Information Identified by the FDA Adverse Event Reporting System (FAERS)

January – March 2025 | Potential Signals of Serious Risks/New Safety Information Identified by the FDA Adverse Event Reporting System…
omufa-performance-reports Drug Test
  • June 27, 2025

OMUFA Performance Reports

Over-the-Counter Monograph Drug User Fee annual performance reports to Congress
Drug Test
  • June 24, 2025

SARMs, Metabolic Modulators and Growth Hormone Secretagogues in Suspected Illegal Medicines, Bought as Sport Performance Enhancers: A Retro‐ and Prospective Study Within the GEON

Data on the presence of illegal products containing SARMs, metabolic modulators and GHS was collected by 13 countries, member of…
Drug Test
  • June 18, 2025

Development of an Optimized Extraction Method to Recover Drug Material From Used Test Strips for Comprehensive Drug Checking

This study aims to develop an optimized method for the extraction of compounds from used test strips for additional mass…
Drug Test
  • June 18, 2025

Monitoring Community Use of Benzodiazepines Through Wastewater‐Based Epidemiology

Validated LC–MS/MS method for 26 prescription BZDs was applied to influent wastewater in Belgium, Latvia, Lithuania and Romania, revealing spatial…
fda-adds-warning-about-serious-risk-of-heat-related-complications-with-antinausea-patch-transderm-scop-(scopolamine-transdermal-system) Drug Test
  • June 18, 2025

FDA adds warning about serious risk of heat-related complications with antinausea patch Transderm Scōp (scopolamine transdermal system)

The antinausea patch Transderm Scōp (scopolamine transdermal system) can increase body temperature and cause heat-related complications, resulting in hospitalization or…
post-warning-letter-meetings-under-gdufa Drug Test
  • June 18, 2025

Post-Warning Letter Meetings Under GDUFA

Post-Warning Letter Meetings Under GDUFA
2025-meeting-materials,-psychopharmacologic-drugs-advisory-committee Drug Test
  • June 17, 2025

2025 Meeting Materials, Psychopharmacologic Drugs Advisory Committee

2025 Meeting Materials, Psychopharmacologic Drugs Advisory Committee
july-18,-2025:-meeting-of-the-psychopharmacologic-drugs-advisory-committee-meeting-announcement-–-07/18/2025 Drug Test
  • June 17, 2025

July 18, 2025: Meeting of the Psychopharmacologic Drugs Advisory Committee Meeting Announcement – 07/18/2025

July 18, 2025: Meeting of the Psychopharmacologic Drugs Advisory Committee Meeting Announcement
clinical-outcome-assessment-(coa)-qualification-program:-frequently-asked-questions Drug Test
  • June 17, 2025

Clinical Outcome Assessment (COA) Qualification Program: Frequently Asked Questions

CDER Clinical Outcome Assessments (COA) Qualification Program: Frequently Asked Questions (FAQs)